Nucleome Therapeutics, an Oxford, UK-based biotechnology company decoding the dark matter of the human genome, raised £37.5M in Series A funding.
The round was led by M Ventures, with participation from JJDC, Pfizer Ventures, British PatientCapital, through its Future Fund: Breakthrough programme, and Oxford Science Enterprises.
The company intends to use the funds to advance its autoimmune disease programs, accelerate expansion of its dark genome atlas and further develop its platform.
Led by CEO Dr Danuta Jeziorska, Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The company has the ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell platform creates 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a pipeline of drug assets, with corresponding biomarkers.
FinSMEs
19/10/2022